Abstract：
BACKGROUND: Mucormycosis presents a diagnostic challenge characterized by high morbidity and mortality rates due to its swift and pervasive nature, which leads to extensive tissue destruction and dissemination. Immunocompromised individuals, notably those with hematological malignancies, are at a heightened risk. First-line antifungal agents include liposomal amphotericin B (L-AMB), posaconazole, and isavuconazole (IVZ), which offer advantages, such as minimal drug interactions and a favorable safety profile. However, the necessity and efficacy of therapeutic drug monitoring (TDM) of IVZ remain unclear.
METHODS: We report a successful case of IVZ therapy in a patient who was intolerant of L-AMB, highlighting the efficacy and pharmacokinetics of IVZ in treating pulmonary mucormycosis. Pharmacokinetic analysis revealed steady plasma IVZ concentrations, emphasizing the importance of monitoring IVZ levels, particularly in patients undergoing renal replacement therapy.
CONCLUSIONS: This case highlights the efficacy of IVZ therapy for mucormycosis and the potential utility of TDM in a specific patient population. Further research is needed to elucidate the optimal IVZ dosing and monitoring strategies to ensure safe and efficacious treatment.
METHODS: We report a successful case of IVZ therapy in a patient who was intolerant of L-AMB, highlighting the efficacy and pharmacokinetics of IVZ in treating pulmonary mucormycosis. Pharmacokinetic analysis revealed steady plasma IVZ concentrations, emphasizing the importance of monitoring IVZ levels, particularly in patients undergoing renal replacement therapy.
CONCLUSIONS: This case highlights the efficacy of IVZ therapy for mucormycosis and the potential utility of TDM in a specific patient population. Further research is needed to elucidate the optimal IVZ dosing and monitoring strategies to ensure safe and efficacious treatment.
摘要：
背景：毛霉菌病由于其迅速和普遍的性质，呈现出高发病率和高死亡率的诊断挑战，导致广泛的组织破坏和传播。免疫受损的个体，尤其是那些患有血液系统恶性肿瘤的患者，风险更高。一线抗真菌剂包括脂质体两性霉素B（L-AMB），泊沙康唑,和伊沙武康唑（IVZ），提供优势，如最小的药物相互作用和良好的安全性。然而,IVZ治疗药物监测(TDM)的必要性和有效性尚不清楚.
方法：我们报告了一例IVZ治疗不耐受L-AMB的患者的成功病例，强调IVZ治疗肺毛霉菌病的疗效和药代动力学。药代动力学分析显示血浆IVZ浓度稳定，强调监测IVZ水平的重要性，特别是在接受肾脏替代治疗的患者中。
结论：该病例强调了IVZ疗法治疗毛霉菌病的有效性以及TDM在特定患者人群中的潜在效用。需要进一步的研究来阐明最佳的IVZ给药和监测策略，以确保安全和有效的治疗。
方法：我们报告了一例IVZ治疗不耐受L-AMB的患者的成功病例，强调IVZ治疗肺毛霉菌病的疗效和药代动力学。药代动力学分析显示血浆IVZ浓度稳定，强调监测IVZ水平的重要性，特别是在接受肾脏替代治疗的患者中。
结论：该病例强调了IVZ疗法治疗毛霉菌病的有效性以及TDM在特定患者人群中的潜在效用。需要进一步的研究来阐明最佳的IVZ给药和监测策略，以确保安全和有效的治疗。
